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Elevated levels of NR2A and PSD-95 in the
lateral amygdala in depression
Beata Karolewicz1, Katalin Szebeni2, Tempestt Gilmore1, Dorota Maciag1,
Craig A. Stockmeier1 and Gregory A. Ordway2
1 Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA
2 Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA
Abstract
Compelling evidence suggests that major depression is associated with dysfunction of the brain
glutamatergic transmission, and that the glutamatergic N-methyl-D-aspartate (NMDA) receptor plays
a role in antidepressant activity. Recent post-mortem studies demonstrate that depression is associated
with altered concentrations of proteins associated with NMDA receptor signalling in the brain. The
present study investigated glutamate signalling proteins in the amygdala from depressed subjects,
given strong evidence for amygdala pathology in depression. Lateral amygdala samples were obtained
from 13–14 pairs of age- sex-, and post-mortem-interval-matched depressed and psychiatrically healthy
control subjects. Concentrations of NR1 and NR2A subunits of the NMDA receptor, as well as NMDA
receptor-associated proteins such as post-synaptic density protein-95 (PSD-95) and neuronal nitric oxide
synthase (nNOS) were measured by Western immunoblotting. Additionally, levels of enzymes involved
in glutamate metabolism, including glutamine synthetase and glutamic acid decarboxylase (GAD-67),
were measured in the same amygdala samples. NR2A protein levels were markedly and significantly
elevated (+115%, p=0.03) in depressed subjects compared to controls. Interestingly, PSD-95 levels
were also highly elevated (+128%, p=0.01) in the same depressed subjects relative to controls.
Amounts of NR1, nNOS, glutamine synthetase, and GAD-67 were unchanged. Increased levels of NR2A
and PSD-95 suggest that glutamate signalling at the NMDA receptor in the amygdala is disrupted in
depression.
Received 30 January 2008 ; Reviewed 20 March 2008 ; Revised 10 April 2008 ; Accepted 25 April 2008 ;
First published online 23 June 2008
Key words : Amygdala, glutamate metabolizing enzymes, neuronal nitric oxide synthase, NMDA
receptor, post-synaptic density protein-95.
Introduction
A rapidly growing body of research studies provides
evidence that major depressive disorder (MDD) is
associated with a dysfunction of glutamate signalling.
Numerous clinical studies demonstrate altered brain
indices of glutamate transmission in depressed sub-
jects. Altered brain glutamate or glutamate/glutamine
levels have been observed in magnetic resonance
spectroscopy (MRS) studies in depressed patients
(Auer et al., 2000 ; Hasler et al., 2007 ; Michael et al.,
2003a,b ; Mirza et al., 2004 ; Pfleiderer et al., 2003 ;
Sanacora et al., 2004) and in serum or plasma of
medicated depressed subjects (Altamura et al., 1993 ;
Kim et al., 1982; Mauri et al., 1998). Post-mortem
brain findings demonstrate a depression-associated
reduction in the expression of genes for glutamate
transporters (EAAT-1, EAAT-2) and the glutamate
synthesizing enzyme, glutamine synthetase, in the
temporal lobe (Choudary et al., 2005). A role of gluta-
mate in depression is also supported by numerous
preclinical studies demonstrating that drugs that
alter glutamate signalling have antidepressant activity
in laboratory animals, and demonstration of anti-
depressant-like behaviour in transgenic animals lack-
ing specific glutamate receptors (see Pittenger et al.,
2007 ; Witkin et al., 2007 for reviews).
Of multiple receptors for glutamate, the N-methyl-
D-aspartate (NMDA) receptor has received the most
Address for correspondence : B. Karolewicz, Ph.D., Department
of Psychiatry, University of Mississippi Medical Center,
2500 North State Street, Jackson, MS 39216-4505, USA.
Tel. : (601) 984-5896 Fax : (601) 984-5899
E-mail : bkarolewicz@psychiatry.umsmed.edu









/ijnp/article/12/2/143/667235 by guest on 04 M
ay 2021
attention with respect to the biology of depression and
its treatment (Kugaya and Sanacora, 2005 ; Pittenger
et al., 2007). The NMDA receptor is a heterooligomeric
structure composed of the NR1 subunit, NR2(A–D)
subunits, and less common NR3(A, B) subunits.
NMDA receptors are embedded in the post-synaptic
density (PSD) of the post-synaptic membrane where
they are anchored by PSD-95 and coupled to cyto-
plasmic signalling molecules, including neuronal
nitric oxide synthase (nNOS; Kornau et al., 1995;
Sheng and Kim, 2002). Activation of NMDA receptors
results in Ca2+ entry and subsequent activation of
nNOS. Human post-mortem studies provide evidence
that radioligand binding to the NMDA receptor is
altered in cerebral cortex from suicide victims and
from depressed subjects (Beneyto et al., 2007 ; Nowak
et al., 1995 ; Nudmamud-Thanoi and Reynolds, 2004).
In addition, low levels of nNOS and elevated levels of
the NR2C subunit of the NMDA receptor have been
reported in the noradrenergic locus coeruleus in MDD
(Karolewicz et al., 2004, 2005b). Interestingly, several
antagonists of NMDA receptor activation demonstrate
antidepressant activity in behavioural models in
laboratory animals (Kugaya and Sanacora, 2005). Of
particular relevance is the demonstration that keta-
mine, a NMDA receptor antagonist, exhibits rapid and
sustained antidepressant activity in humans (Berman
et al., 2000 ; Zarate et al., 2006). Together, these find-
ings demonstrate compelling evidence that glutamate
signalling through the NMDA receptor is disrupted in
depression.
In the present study, levels of several proteins
involved in glutamate signalling through the NMDA
receptor were measured in brain tissue from subjects
who had clinically defined depressedmood at the time
of death, and psychiatrically normal control subjects.
The NMDA receptor signalling proteins chosen for
study were relevant subunits of the NMDA receptor
(NR1 and NR2A), a major anchoring and scaffolding
protein associated with the receptor (PSD-95), and an
intracellular signalling protein (nNOS) linked to the
receptor. In addition two major glutamate metabolic
enzymes glutamine synthetase (GS) and glutamic acid
decarboxylase (GAD-67) were investigated. The area
of the brain chosen for study was the lateral nucleus of
amygdala. The amygdala has long been implicated in
the pathobiology of depressive disorders and suicide
(Bowley et al., 2002 ; Cheetham et al., 1989 ; Drevets
et al., 2002 ; Klimek et al., 2002 ; Sheline et al., 1998).
Glutamatergic inputs from the prefrontal cortex
and thalamus enter amygdala at the lateral level
(Carmichael and Price, 1995 ; McDonald, 1998),
making this amygdala subregion a key brain region in
receiving and processing cortical and thalamic infor-
mation transmitted via glutamatergic transmission.
The NR1 and NR2A subunits were specifically chosen
for study because the NMDA receptor in the mature
lateral amygdala is largely composed of these two
subunits (Lopez de Armentia and Sah, 2003 ; Radley
et al., 2007).
Materials and methods
Psychiatric autopsy and tissue collection
Post-mortem brain samples were collected at autopsy
from a total of 28 subjects at the Cuyahoga County
Coroner’s Office in Cleveland, OH, USA. Informed
written consent was obtained from the legal next-of-
kin of all subjects. Next-of-kin were interviewed
and retrospective psychiatric assessments were con-
ducted in accordance with Institutional Review
Board policies at Case Western Reserve University
and the University of Mississippi Medical Center.
A trained interviewer administered the Schedule
for Affective Disorders and Schizophrenia : lifetime
version (SADS-L) and/or the Structured Clinical In-
terview for DSM-IV Psychiatric Disorders (SCID-IV) to
knowledgeable next-of-kin of subjects in the study.
A total of 14 subjects were studied that had
the common feature of depressed mood: 11 subjects
met clinical criteria for MDD and three subjects met
criteria for adjustment disorder with depressed mood
based on DSM-IV-R criteria. One MDD subject had
a co-existing diagnosis of dysthymic disorder, and
one MDD subject had a diagnosis of alcohol abuse
(Table 1).
Fourteen subjects did not meet criteria for Axis I
disorder (termed psychiatrically healthy controls) ex-
cept for nicotine dependence as noted (see Table 1).
Among 14 depressed individuals, 12 were suicide
victims, and two died due to the other causes such as a
homicide or pulmonary embolism (Table 1). Blood
and urine samples from all subjects were examined by
the coroner’s office for psychotropic medications and
substances of abuse, including ethanol (Table 1).
No antidepressant drugs were detected in the post-
mortem toxicology screening of subjects in the present
study (Table 1). Fourteen depressed subjects and
14 psychiatrically healthy controls were arranged
into 14 pairs, matched as closely as possible for age,
gender, post-mortem interval (PMI), tissue pH and
smoking history. As specified above, one MDD subject
had a diagnosis of alcohol abuse ; this subject was
matched with an alcohol-dependent control subject
with no other psychiatric disorders.
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Dissection and anatomical positioning of
measurements
Tissue was collected from frozen blocks containing
the right amygdaloid complex. Frozen blocks were
cut into 50-mm-thick sections for collecting tissue for
Western blotting and 20-mm-thick sections for his-
tology. The 20-mm-thick tissue sections collected at
1-mm intervals along the anterior–posterior extent of
the amygdala were processed for acetylcholinesterase.
Acetylcholinesterase histology (as described pre-
viously by Biegon and Wolff, 1986 and Karolewicz
et al., 2005a) was used to create anatomical templates
for anatomical positioning and as a guide for the
dissection of the lateral nucleus. For all subjects, the
anatomical position for collection of tissue punches of
the lateral amygdala for Western blotting was estab-
lished approximately midway along the anterior–
posterior extent of the amygdala (Figure 1). Tissue
punches (diameter 5 mm) containing the lateral
nucleus were collected in centrifuge tubes and stored
at x80 xC until assayed.
Western blotting
Tissue samples were prepared as published pre-
viously (Karolewicz et al., 2005b). Samples were
homogenized in ice-cold TE buffer (10 mM Tris–HCl
and 1 mM ethylene-diaminetetraacetate ; EDTA) con-
taining protease inhibitors (Protease Inhibitor Cocktail
Tablets – CompleteTM, Boehringer Mannheim GmbH,
Mannheim, Germany). Total protein concentrations
Table 1. Demographic characteristics of subjects
Parameter Controls (n=14) Depressed (n=14)
Age (yr) (mean¡S.E.M.) 53¡4 54¡4
Age range 27–74 30–73
PMI (h) (mean¡S.E.M.) 18¡1 19¡2
PMI range 6–26 5–33
PH (mean¡S.E.M.) 6.68¡0.07 6.55¡0.07
PH range 5.99–6.96 6.15–6.91
Time in freezer (TF)
(months) (mean¡S.E.M.)
121¡5 132¡8
TF range 81–158 61–181
Gender (F/M) 1/13 1/13
Medication historya 0/14 2/14 (sertraline)




Drugs detected (n=3) (codeine,
phenobarbital, phenytoin)
Ethanol (n=1)
Ethanol (n=1) CO (n=2)
CO (n=1)
Cause of death Heart disease (n=9) Suicide (n=12) (shotgun, n=5 ;
CO poisoning, n=3 ; hanging, n=2 ;
drowning, n=1 ; slit wrists, n=1)
Hypertension (n=1)
Aneurysm (n=1) Other causes (n=2) (pulmonary
embolism, homicide)Accidental CO poisoning (n=1)
Homicide (n=1)
Thrombophlebitis (n=1)
Diagnosis Alcohol dependence (n=1) MDD (n=9)
Phobia (heights) (n=1) MDD and dysthymic disorder (n=1)
MDD and alcohol abuse (n=1)
Adjustment disorder with
depressed mood (n=3)
Smoking Smokers (n=6) Smokers (n=6)
History of smoking (n=3) History of smoking (n=3)
PMI, Post-mortem interval ; CO, carbon monoxide ; MDD, major depressive disorder.
a Treatment with antidepressants within 4 wk of time of death. The average ages, PMI, pH and TF of depressed and control
subjects were not statistically different.
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for all samples were determined using the bicincho-
ninic acid (BCA) method (Pierce Biotechnology Inc.,
Rockford, IL, USA). Samples were mixed with sample
buffer [125 mM Tris base, 20% glycerol, 4% SDS, 10%
mercaptoethanol, 0.05% Bromophenol Blue (pH 6.8)]
and heated at 95 xC for 8 min. Solubilized protein
(20 mg per lane) was subjected to 10% Criterion Precast
Tris–HCl gel electrophoresis (Bio-Rad Laboratories,
Hercules, CA, USA) and transferred to nitrocellulose
membranes (Hybond ECL; Amersham Biosciences,
Piscataway, NJ, USA). Membrane blots were blocked
in 5% non-fat milk/TBS [20 mM Tris base and 0.5 M
NaCl (pH 7.5)] or 5% non-fat milk/PBS [137 mM NaCl,
2.7 mM KCl, 8 mM Na2HPO4 and KH2PO4 (pH 7.4)] for
2 h, then incubated (overnight at 4 xC) with primary
antibody (see Antibodies section below). Membranes
were washed twice for 15 min in TBS (or PBST) buffer
and incubated with secondary anti-mouse antibody
for NR1, PSD-95, nNOS, GS, actin (diluted 1:2000;
Amersham Biosciences, no. NA931) and anti-rabbit
secondary antibody for NR2A and b-tubulin (diluted
1:5000 ; Amersham Biosciences, no. NA934). After
incubation, blots were washed three times for 15 min
and developed using enhanced chemiluminescence
detection (ECL; PerkinElmer Life Sciences Inc.,
Boston, MA, USA) and immediately exposed to film
(Hyperfilm ECL, Amersham Biosciences).
Antibodies
All antibodies used in this study were commercially
available and have been used previously to detect
NR1, NR2A, PSD-95, nNOS, GS, and GAD-67 in
numerous regions of the human and rat brain as well
as in-vitro studies (Gerlach et al., 2001 ; Karolewicz
et al., 2004, 2005b, 2008 ; Kronfeld et al., 2000;
Kristiansen et al., 2006 ; Ling et al., 2005). Mouse
monoclonal antibodies were used to label NR1 subunit
(1 :1000 ; BD Biosciences/Pharmingen, San Diego,
CA, USA; no. 556308), PSD-95 (1 :1000 ; Upstate Bio-
technology, Lake Placid, NY, USA; no. 05-494), nNOS
(1 :1000 ; BD Biosciences/Transduction Laboratories,
Franklin Lakes, NJ, USA; no. 610309), GS (1 :1000; BD
Biosciences/Transduction Laboratories ; no. 610518),
and GAD-67 (1 :1000 ; Chemicon, Temecula, CA, USA,
no. MAB5406). NR2A subunit was labelled using
rabbit polyclonal antibodies diluted 1:500 (Novus
Biologicals, Littleton, CO, USA; no. NB 300-105). As a
control for transfer and loading, actin or b-tubulin was
detected on blots using an anti-actin (Chemicon, no.
MAB1501) or anti-tubulin (Abcam Inc., Cambridge,
MA, USA; no. ab6046) antibody.
Experimental design and data analysis
Immunoreactivities of glutamate-related proteins were
investigated in 13–14 depressed subjects and 13–14
matched normal control subjects. Pairs of subjects
were immunoblotted on the same gel (maximum four
pairs) with duplicates on separate gels. In order to
minimize inter-blot variability and to aid in quantify-
ing blots, each gel was loaded with three concen-
trations of a cortical tissue standard consisting of 10,
20, and 40 mg total protein. The tissue standard was
dissected from prefrontal cortex (area 10) of one con-
trol subject and the same cortical tissue standard was
used for all experimental gels. Band densities were
analysed using MCID Elite 7.0 (Imaging Research,
St Catherine’s, ON, Canada). Linear regression
(GraphPad Prism 4.0 ; GraphPad Software Inc., San
Diego, CA, USA) was used to plot a standard curve for
each gel, from which relative optical density (ROD)
values of samples were converted to cortical standard
protein units for each experimental sample for each
gel. In order to control for accuracy of tissue loading
and efficiency of transfer, data were normalized to
actin or tubulin detected on the same blots. The final
data are expressed in cortical standard protein units
and presented as a ratio of (protein of interest)/(actin
or tubulin).
Statistical analyses
Data were analysed statistically using a two-tailed
paired Student’s t test (GraphPad Prism 4.0). Linear
regression analysis was performed to test for associ-








Figure 1. Digital image of a coronal section of the amygdala
stained histochemically for acetylcholinesterase. The
acetylcholinesterase staining preparation was used to
visualize the lateral amygdala and to distinguish it from
neighbouring nuclei : basal (B), accessory basal (AB), central
(C), medial (M), cortical (CO).
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each protein investigated. If a significant correlation
between protein immunoreactivities and ones of these
variables was observed (p<0.05), analysis of covari-
ance (ANCOVA) was used to correct the test for the
effect of diagnosis on the protein expression. Summary
statistics are reported as the mean¡S.E.M. A p value
<0.05 was considered significant.
Results
Relationship between optical density and total
protein concentration
In order to determine the relationship between optical
density values and the concentrations of protein
immunoreactivities, 10, 20, and 40 mg total cortical
protein (standard) was immunoblotted with all anti-
bodies used in this study. Analyses of blots revealed a
linear relationship between optical density values and
protein concentrations (Figure 2). All measurements of
control and depressed samples fell within the linear
range of these standard plots.
NMDA receptor subunits
For NMDA receptor subunits, immunoreactive bands
corresponding to molecular masses of 120 kDa and
180 kDa for NR1 and NR2A, respectively, were ob-
served in homogenates of lateral amygdala (Figure 3a).
Averaged NR1 immunoreactivities from depressive
(1.22¡0.15) and control subjects (1.36¡0.20) were not
statistically different (t=1.1, d.f.=13, p=0.28). There
were no significant correlations between amounts of
NR1 and pH, PMI, age or TF. The amount of NR2A
immunoreactivity from depressed subjects (1.38¡0.36)
was significantly higher (+115%) than that from
control subjects (0.64¡0.11, t=2.4, d.f.=12, p=0.03).
A significant negative correlation was found between
TF and amounts of NR2A immunoreactivity in de-
pressed subjects (r2=0.48, p=0.008). Using ANCOVA
with TF as a covariate for NR2A, an effect of diagnosis
on this subunit was still detected (p=0.011).
NMDA receptor-interacting proteins
PSD-95 and nNOS immunoreactivities appeared as
bands with molecular masses of 95 kDa and 160 kDa,
respectively (Figure 3b). Averaged PSD-95 immuno-
reactivities from depressive (1.49¡0.26) and control
subjects (0.65¡0.12)were statisticallydifferent (+128%,
t=2.9, d.f.=13, p=0.01 ; Figure 4). Linear regression
analysis showed negative correlations between PMI
and amounts of PSD-95 immunoreactivity in controls
(r2=0.32, p=0.04) and between TF and PSD-95
immunoreactivity in depressed subjects (r2=0.32, p=
0.03). Nevertheless, using ANCOVA with PMI and TF
as a covariates, a significant effect of depression for
PSD-95 was still detected (p=0.002).
Amounts of nNOS immunoreactivity in depressives
(1.75¡0.16) and control subjects (1.89¡0.16) were not
significantly different (t=0.68, d.f.=13 p=0.5). There
was a significant negative correlation between PMI
and amounts of nNOS immunoreactivity in depressed
subjects (r2=0.45, p=0.008). Using ANCOVA with pH
as a covariate for nNOS did not change the statistical
outcome of the analysis (p=0.998).
Glutamate metabolizing enzymes
GS immunoreactivity appeared as a band at 45 kDa
(Figure 3c) and amounts of GS immunoreactivity were
unchanged in depressed (0.84¡0.09) compared to
control subjects (0.89¡0.06, t=0.43, d.f.=13, p=0.67 ;
Figure 5). There was a significant positive correlation
between pH and amounts of GS immunoreactivity in
control subjects (r2=0.36, p=0.02). Using ANCOVA
with pH as a covariate for GS, a main effect for diag-
nosis on GS was not detected (p=0.98). GAD-67 was
revealed as a single band at 67 kDa (Figure 3c).
Average amounts of GAD-67 immunoreactivity in
control subjects (1.05¡0.11) and in depressed subjects
(0.95¡0.08) were not statistically different (t=0.89,
d.f.=13, p=0.38 ; Figure 5). There were no significant
correlations between amounts of GAD-67 and pH, age,
PMI or TF.
Correlations of immunoreactivities
The possibility that amounts of certain proteins in the
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Figure 2. Relationship between the optical density values
of Western-blotted protein immunoreactivities and total
protein concentration for NR1, NR2A, PSD-95, nNOS, GS,
GAD-67, actin, and tubulin. Wells were loaded with three
concentrations of cortical standard (dissected from a healthy
control subject) consisting of 10, 20, and 40 mg total protein.
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was investigated. Amounts of NR2A immuno-
reactivity were highly positively correlated with
PSD-95 immunoreactivity only in depressed subjects
(r2=0.79, p<0.0001). There were no significant corre-
lations between NR2A and nNOS or PSD-95 and
nNOS in both control and depressed subjects (data not
shown).
Discussion
The present study is the first to analyse the levels
of several glutamate signalling-related biological
markers in post-mortem amygdala from depressed
subjects. Evidence is provided that amounts of the
NR2A subunit and its anchoring protein, PSD-95, are
robustly elevated in the lateral amygdala of depressed
subjects compared to psychiatrically healthy control
subjects. Increased expression of NR2 subunits of
the NMDA receptor may be a common pathology in
depression since higher levels of the NR2C subunit
were previously reported in the noradrenergic locus
coeruleus in depressed subjects (Karolewicz et al.,
2005b). Interestingly, recent research points to clinical
efficacy of NMDA receptor antagonism in depression,
i.e. recent clinical studies have shown that a single
intravenous dose of ketamine, an NMDA receptor
antagonist, produces robust, rapid, and relatively
sustained antidepressant effects in treatment-resistant
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Figure 4. Amounts of NR1, NR2A, PSD-95, and nNOS
immunoreactivities in the lateral amygdala from control
subjects (#, n=13–14) and depressed subjects ($, n=13–14).
Significant increases in the NR2A and PSD-95
immunoreactivities (+115% and +128%, respectively) were
observed in depressed subjects as compared to controls.
Normalized optical density values for the individual subjects




































Figure 5. Amount of glutamine synthetase (GS) and GAD-67
immunoreactivity from control subjects (#, n=14) and
depressed subjects ($, n=14) in the lateral amygdala.
Normalized optical density values for the individual subjects































































Figure 3. Immunoblots of (a) NR1, NR2A, and actin ; (b) nNOS, PSD-95, and actin and (c) GS, GAD-67, and tubulin from three
representative pairs of controls (Cont) and depressed subjects (Dep) used in the analysis. Each well was loaded with 20 mg total
protein.
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Preclinical research also suggests that inhibition of
NMDA receptor, as well as inhibition of intracellular
signalling cascades including nNOS that are linked to
the NMDA receptor, exhibit antidepressant-like effects
in animal screening procedures (Paul, 2001 ; Paul and
Skolnick, 2003). Interestingly, NR2A knockout mice
show antidepressant-like profiles in animal models,
as compared to wild-type controls (Boyce-Rustay and
Holmes, 2006). Moreover, a selective NR2B antagonist
Ro25-6981 exhibits antidepressant-like properties in
mice (Maeng et al., 2007). A preliminary clinical
study has demonstrated the benefit of supplemen-
tation with zinc, a non-selective NMDA receptor
antagonist, in antidepressant therapy (Nowak et al.,
2003). Collectively, current research suggests that the
NMDA receptor complex is abnormal in depression
and regulation of NMDA receptor signalling in
critical brain circuits may represent a strategy for
the development of effective and rapid-acting anti-
depressants.
The abnormalities at the excitatory synapse, as re-
vealed by our post-mortem research, may occur in re-
sponse to abnormal levels of glutamate in depression.
Several lines of evidence indicate altered glutamate or
glutamate/glutamine levels in multiple brain regions
in depressed patients (Auer et al., 2000 ; Hasler et al.,
2007 ; Michael et al., 2003a,b ; Mirza et al., 2004 ;
Pfleiderer et al., 2003 ; Sanacora et al., 2004). It has been
well established that glia play a key role in glutamate
neurotransmission, including glutamate metabolism
and recycling, therefore depression-associated reduc-
tions in the density of these cells in prefrontal cortex
(Miguel-Hidalgo et al., 2000 ; Ongur et al., 1998 ;
Rajkowska et al., 1999 ; Si et al., 2004) and amygdala
(Bowley et al., 2002 ; Hamidi et al., 2004) may also
contribute to altered synaptic glutamate in depression.
GS gene expression has been shown to be reduced in
the prefrontal cortex in depression (Choudary et al.,
2005), which could also contribute to altered glutamate
levels and compensatory changes in glutamate re-
ceptors. Since GS is exclusively expressed in astrocytes
and a reduced density of astrocytes has been consist-
ently reported in depression (see above) ; we hypo-
thesized that GS protein immunoreactivity would
be reduced in the amygdala. However, the present
findings demonstrate unaltered levels of GS in the
lateral amygdala in depression. It is conceivable that
unchanged levels of GS may indicate (1) unchanged
density of astrocytes in the amygdala in depression,
(2) a compensatory increase in GS protein expression
in remaining astrocytes, or (3) GS expression may
be turned on in cells other than astrocytes during
depression. One other study has also reported
unchanged GS immunoreactivity in the prefrontal
cortex in depression (Toro et al., 2006).
Glutamate is an immediate precursor for GABA,
and reductions in GABA levels are consistently re-
ported in neuroimaging studies in depression (Hasler
et al., 2007 ; Sanacora et al., 1999, 2004). In addition,
post-mortem analyses demonstrate a significant re-
duction in the density and size of GABAergic inter-
neurons immunoreactive for calbindin in the dorso-
lateral prefrontal cortex in depression (Rajkowska
et al., 2007). Reduced levels of GAD-67 and GAD-65
were previously reported in cerebellum in MDD sub-
jects (Fatemi et al., 2005). We expected to find lower
GAD-67 protein levels in depression in the present
study. However, GAD-67 levels in the lateral amyg-
dala were unchanged in depressed subjects. Further
studies aimed to investigate protein levels and/or
activity of GAD-65, another isoforms of GAD (Bu et al.,
1992) are needed to fully address the status of GABA
synthesis in the amygdala in depression.
The NMDA receptor in the mature lateral amygdala
is largely composed of the NR1 subunit, a mandatory
subunit, and the regulatory NR2A subunit (Lopez de
Armentia and Sah, 2003 ; Radley et al., 2007). To date,
few studies have investigated NMDA receptors in
post-mortem brain from depressed subjects. In this
study, NR1 subunit immunoreactivity was unchanged
in the amygdala in depression, despite a significant
elevation of NR2A subunit immunoreactivity. Un-
changed levels of NR1 subunit in amygdala in de-
pression is consistent with our previous observations
in the locus coeruleus and cerebellum of depressed
subjects (Karolewicz et al., 2005b) and no changes in
NR1 immunoreactivity in subregions of the hippo-
campal dentate gyrus and in the orbitofrontal cortex
(Toro and Deakin, 2005).
Only two previous investigations have measured
PSD-95 in brain tissues form depressed subjects.
Normal levels in depressed subjects were reported
for PSD-95 mRNA in the striatum (Kristiansen and
Meador-Woodruff, 2005) and for PSD-95 protein in
the hippocampus and orbitofrontal cortex (Toro and
Deakin, 2005). In the lateral amygdala, we found
markedly elevated levels of PSD-95 in depressives as
compared to matched control subjects. These findings
suggest that PSD-95 involvement in depression
is neuroanatomically limited. PSD-95 belongs to
the large family of membrane-associated guanylate
kinases (MAGUKs) and is exclusively localized to
dendritic spines at glutamatergic synapses (Hunt et al.,
1996). PSD-95 binds to the NMDA receptor subunits
NR2A and NR2B (Kornau et al., 1995) and also couples
synaptic NMDA receptors to downstream signalling
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molecules such as nNOS (Brenman et al., 1996 ; Sattler
et al., 1999) which serves as an intracellular mediator
of NMDA receptor activation. MAGUKs appear to
play a fundamental role in the transport, anchoring,
and signalling of glutamate NMDA receptors. In
the present study, the increase in PSD-95 immuno-
reactivity in depressives was highly correlated with an
increase in NR2A subunit immunoreactivity. Hence,
the depression-associated elevation in levels of PSD-95
imply increased intracellular trafficking, synaptic
delivery, and coupling of the NMDA receptors to
intracellular signalling cascades in the amygdala. The
lateral amygdala receives its major glutamatergic
afferents from the cortical areas and from the thalamus
(Mahanty and Sah, 1999). These inputs activate
synapses containing both NMDA and non-NMDA
receptors. Depression-associated perturbations in
markers of glutamate transmission in cortical regions,
as revealed by imaging and post-mortem cell counting
studies (Hasler et al., 2007 ; Rajkowska et al., 1999,
2005 ; Sanacora et al., 2004 ; Si et al., 2004) could result
in abnormalities of glutamatergic signalling in cortical
projection areas, including the lateral amygdala.
Recent imaging studies in depressed humans point to
reduced prefrontal cortical function that is linked to
increased amygdala activity (Drevets, 1999 ; Siegle
et al., 2007). Elevated levels of NR2A/PSD-95 may
reflect an adaptive response to altered cortical input to
the amygdala and may contribute to altered amygdala
activity in depression.
A shortcoming of the present study is that NMDA
receptor subunits were measured as a total pool of
proteins that included intracellular pools of un-
assembled proteins and assembled NMDA receptors
expressed at the cell membrane, complicating the
prediction of functional significance. However, it has
been proposed that the NR1 subunit, which is syn-
thesized in great excess (y10-fold), accounts for most
of the intracellular pool (Huh and Wenthold, 1999).
The excess production of NR1 increases the chance
that NR2 subunits will find NR1 partners. In contrast
to NR1, only a small percentage of NR2 subunit pro-
tein is intracellular (Huh and Wenthold, 1999) ; almost
all NR2 subunits are expressed on the cell surface.
Hence, the total number of functional NMDA re-
ceptors appears to be controlled by expression of the
NR2 subunits (Prybylowski et al., 2002). Based on this,
the elevation of NR2A immunoreactivity in homo-
genates of lateral amygdala from depressives is likely
to reflect an increase of functional surface NMDA re-
ceptors. Of course, a depression-associated disruption
in the normal cellular trafficking of NMDA receptor
subunits cannot be ruled out with the present data.
Treatment of depression may contribute to the
adaptive changes seen in the human post-mortem
brain. This study includes only two subjects with a
reported history of medication with antidepressants at
some point during their lifetime. In both cases, the
selective serotonin reuptake inhibitor, sertraline, was
prescribed. However, the presence of this drug was
not revealed in the post-mortem toxicology screening
and both subjects died as a result of suicide (Table 1).
One of these two subjects had PSD-95 and NR2A
levels unchanged compared to their matched control,
while the other subject had levels higher than that of
the matched control subject and comparable to the
average level of immunoreactivity of depressive sub-
jects lacking the drug exposure. It can be inferred from
these observations that the past antidepressant drug
treatment is unlikely to contribute to the elevation of
PSD-95 or NR2A levels observed in the depressed
subjects.
In summary, a marked elevation of NR2A sub-
unit and PSD-95 immunoreactivities in the lateral
amygdala of depressed subjects compared to
control subjects were observed. A strong correlation
between levels of NR2A subunit and PSD-95
immunoreactivities were observed in depressed
subjects. Changes in NR2A and its anchoring
protein in depression may reflect an adaptive
response to a decreased excitatory input from cortical
regions. Further studies of the glutamatergic signal-
ling markers in depression involving non-NMDA
ionotropic receptors, metabotropic receptors, and
glutamate transporters will lead to a better under-
standing of the role of glutamate in the pathology of
depression.
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